ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?

Mazen Noureddin; Manal F. Abdelmalek

doi:10.1002/hep.32399

ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	295-297
Number of pages	3
Journal	Hepatology
Volume	76
Issue number	2
DOIs	https://doi.org/10.1002/hep.32399
State	Published - Aug 2022

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.32399

Cite this

@article{08b8bf2bb24045cb88163a435d8e3384,

title = "ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?",

author = "Mazen Noureddin and Abdelmalek, {Manal F.}",

note = "Funding Information: Dr. Abdelmalek consults for and received grants from Madrigal, Hanmi, and NovoNordisk. She consults for 89Bio, Theratherapeutics, BMS, NGM Bio, Inventiva, and SonicIncytes. She is on the speakers{\textquoteright} bureau for CLDF, Clinical Care Options, Fishawack Inc., and Terra Firma LLC. She received grants from Allergan, BMS, Galmed, Intercept, Viking, Genentech, Boehringer‐Ingelheim, Celgene, and Inventiva. Dr. Noureddin owns stock in and received grants from Viking. He consults for and received grants from Madrigal, Gilead, and Pfizer. He consults for 89Bio, Altimmune, CohBar, Cytodyn, Intercept, Pfizer, Novo Nordisk, Blade, Echosens, Fractyl, NorthSea, Terns, Siemens, and Roche Diagnostic. He received grants from Allergan, BMS, Galmed, Galectin, Genfit, Conatus, Enanta, Novartis, Shire, and Zydus.",

year = "2022",

month = aug,

doi = "10.1002/hep.32399",

language = "English (US)",

volume = "76",

pages = "295--297",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Wiley",

number = "2",

}

TY - JOUR

T1 - ACE inhibitors

T2 - The secret to prevent cirrhosis complications and HCC in NAFLD?

AU - Noureddin, Mazen

AU - Abdelmalek, Manal F.

N1 - Funding Information: Dr. Abdelmalek consults for and received grants from Madrigal, Hanmi, and NovoNordisk. She consults for 89Bio, Theratherapeutics, BMS, NGM Bio, Inventiva, and SonicIncytes. She is on the speakers’ bureau for CLDF, Clinical Care Options, Fishawack Inc., and Terra Firma LLC. She received grants from Allergan, BMS, Galmed, Intercept, Viking, Genentech, Boehringer‐Ingelheim, Celgene, and Inventiva. Dr. Noureddin owns stock in and received grants from Viking. He consults for and received grants from Madrigal, Gilead, and Pfizer. He consults for 89Bio, Altimmune, CohBar, Cytodyn, Intercept, Pfizer, Novo Nordisk, Blade, Echosens, Fractyl, NorthSea, Terns, Siemens, and Roche Diagnostic. He received grants from Allergan, BMS, Galmed, Galectin, Genfit, Conatus, Enanta, Novartis, Shire, and Zydus.

PY - 2022/8

Y1 - 2022/8

UR - http://www.scopus.com/inward/record.url?scp=85125418278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125418278&partnerID=8YFLogxK

U2 - 10.1002/hep.32399

DO - 10.1002/hep.32399

M3 - Editorial

C2 - 35124826

AN - SCOPUS:85125418278

SN - 0270-9139

VL - 76

SP - 295

EP - 297

JO - Hepatology

JF - Hepatology

IS - 2

ER -

ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this